Related Experiment Video
Updated: Aug 23, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity
Mark S Duxbury1, Hiromichi Ito, Michael J Zinner
1Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Background:
The c-Src tyrosine kinase is a determinant of malignant cellular behavior in a variety of human cancers. We sought to determine the effect of suppressing c-Src expression on pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Study Design:
PANC1, MIAPaCa2, BxPC3, and Capan2 pancreatic adenocarcinoma cell lines were studied. Expression of c-Src was determined by Western blot analysis. c-Src kinase activity was determined by in vitro kinase assay. RNA interference was used to suppress c-Src expression. Gemcitabine-induced cytotoxicity was determined by tetrazolium reduction assay and caspase profiling was performed. The effect of Src-specific siRNA on Akt activity was quantified.
Results:
Src expression and kinase activity in cell lines were directly correlated with gemcitabine chemoresistance. c-Src-specific siRNA suppressed c-Src expression and kinase activity. c-Src-specific siRNA increased gemcitabine-induced, caspase-mediated apoptosis. Akt activity was decreased by suppression of c-Src expression.
Conclusions:
c-Src is a determinant of pancreatic adenocarcinoma chemoresistance and represents a potential target for therapeutic intervention.
Insights
Suppressing c-Src tyrosine kinase (Src) in pancreatic cancer cells enhances sensitivity to gemcitabine chemotherapy. This study shows Src inhibition increases apoptosis and decreases Akt activity, suggesting Src as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- c-Src tyrosine kinase (Src) is implicated in malignant behaviors across various human cancers.
- Pancreatic adenocarcinoma exhibits chemoresistance, necessitating novel therapeutic strategies.
- The role of Src in gemcitabine chemosensitivity in pancreatic cancer remains to be fully elucidated.
Purpose of the Study:
- To investigate the impact of suppressing c-Src expression on pancreatic adenocarcinoma cell sensitivity to gemcitabine.
- To determine if c-Src inhibition can overcome gemcitabine chemoresistance.
- To explore the molecular mechanisms underlying c-Src's role in chemoresistance.
Main Methods:
- Utilized four pancreatic adenocarcinoma cell lines (PANC1, MIAPaCa2, BxPC3, Capan2).
- Assessed c-Src expression and kinase activity via Western blot and in vitro kinase assays.
- Employed RNA interference (siRNA) to suppress c-Src expression and quantified gemcitabine-induced cytotoxicity, apoptosis, and Akt activity.
Main Results:
- c-Src expression and kinase activity positively correlated with gemcitabine chemoresistance in the studied cell lines.
- Suppression of c-Src using siRNA effectively reduced c-Src expression and kinase activity.
- c-Src suppression significantly enhanced gemcitabine-induced, caspase-mediated apoptosis and decreased Akt activity.
Conclusions:
- c-Src tyrosine kinase is a critical determinant of chemoresistance in pancreatic adenocarcinoma.
- Targeting c-Src represents a promising therapeutic strategy to improve gemcitabine efficacy in pancreatic cancer.
- Inhibition of c-Src may sensitize pancreatic cancer cells to chemotherapy by modulating apoptotic pathways and Akt signaling.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:56Treatment Resistant Cancers